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Abstract
Recurrent use of prescription opioid analgesics by chronic pain patients may result in opioid
dependence, which involves implicit neurocognitive operations that organize and impel craving
states and compulsive drug taking behavior. Prior studies have identified an attentional bias (AB)
towards heroin among heroin dependent individuals. The aim of this study was to determine
whether opioid-dependent chronic pain patients exhibit an AB towards prescription opioidrelated
cues. Opioid-dependent chronic pain patients (n = 32) and a comparison group of non-dependent
opioid users with chronic pain (n = 33) completed a dot probe task designed to measure opioid
AB. Participants also rated their opioid craving and self-reported arousal associated with opioid-
related and neutral images, pain severity, and relief from pain treatments. Repeated-measures
ANOVA revealed a significant group (opioid-dependent vs. non-dependent opioid user) ×
presentation duration (200 ms. vs. 2000 ms.) interaction, such that opioid-dependent individuals
evidenced a significant AB towards opioid cues presented for 200 ms but not for cues presented
for 2000 ms, whereas non-dependent opioid users did not exhibit a significant mean AB at either
stimulus duration. Among opioid-dependent individuals, 200 ms opioid AB was significantly
associated with opioid craving, while among non-dependent opioid users, 200 ms opioid AB was
significantly associated with relief from pain treatments. Furthermore, dependent and non-
dependent opioid users experienced opioid cues as significantly more arousing than neutral cues.
Opioid dependence among chronic pain patients appears to involve an automatic AB towards
opioid-related cues. When coupled with chronic pain, attentional fixation on opioid cues may
promote compulsive drug use and addictive behavior.
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Opioid therapy for chronic pain conditions often provides effective analgesia but confers
significant risk for developing opioid use disorders in a subset of vulnerable individuals
(Denisco, Chandler, & Compton, 2008; Passik, 2009). Prolonged, medically-appropriate
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opioid use produces physical dependence symptoms via neuroadaptations resulting in
tolerance to opioids, withdrawal when opioids are discontinued, and, in some instances,
opioid-induced hyperalgesia (Chu, Angst, & Clark, 2008), a condition in which longer
exposure to opioids tends to induce hypersensitivity to pain. These physical symptoms of
opioid dependence are natural responses to extended use of opioids, and do not signal the
presence of an opioid use disorder. In contrast, prescription opioid dependence as defined by
DSM-IV involves not only physical dependence symptoms, but behavioral symptoms as
well, including: taking higher doses than intended; an inability to reduce or stop taking
opioids; spending substantial amounts of time using, obtaining, recovering, or thinking of
opioids; and continued use in spite of adverse physical or psychological consequences
(Zacny, Bigelow, Compton, Foley, Iguchi, & Sannerud, 2003). However, some believe that
these behavioral criteria for dependence are inappropriate for opioid-using chronic pain
patients, because patients who take opioids as prescribed may be unable to reduce their
opioid use or may continue opioid use in spite of adverse health consequences due to the
intractability of their chronic pain condition. As such, many pain medicine and addiction
specialists use the criteria for opioid addiction as established by the American Pain Society
(2002) to identify the presence of disordered opioid use among chronic pain patients,
including symptoms of impaired control over opioid use, compulsive opioid use, continued
use despite harm, and craving (Wilson, 2007). Although less serious forms of opioid misuse
like unauthorized dose escalation are relatively common and may not indicate disordered
use of opioids, addictive tendencies among prescription opioid users may be signified by
serious opioid misuse behaviors such as selling medication or injecting oral formulas (Ives
et al. 2006; Sullivan et al. 2010). Indeed, such aberrant drug-taking behaviors are believed to
mark the transition from sanctioned use of opioids to the development of opioid use
disorders and addiction (Butler et al., 2007).
Like other forms of substance dependence, prescription opioid use disorders may involve
implicit neurocognitive operations that organize and impel craving states and aberrant drug
taking (Stacy & Wiers, 2010). Repeated substance use is thought to establish automatic
drug-use action schemas, i.e., memory systems that compel and coordinate consumption of
the substance through automatized sequences of stimulus-bound, context-dependent
behavior, including the biasing of attention towards substance-relevant stimuli (Garland et
al., 2011a; Pierce & Vanderschuren, 2010; Tiffany, 1990). As chronic pain patients engage
in recurrent opioid use or misuse, opioid cues (e.g., the sight of a pill bottle or a syringe used
for illicit intravenous drug use) may become salient both through the pharmacologic reward
induced by opioid consumption, as well as through the analgesic effects of the drug which
remove or allay the aversive experience of pain (Fields, 2004). Presumably, the incentive
salience of opioid cues may increase over time as opioid dependence becomes more deeply
entrenched via the process of sensitization of the mesolimbic dopamine system (Robinson &
Berridge, 2008). Insofar as cues associated with past drug use are motivationally salient for
habitual drug users, they are able to consequently capture attention, which in turn amplifies
their motivational salience (Franken 2003). This phenomenon, known as addiction
attentional bias (AB), is associated with craving and increased drug use (Field, Munafo, &
Franken, 2009), predicts relapse (e.g., Garland, Franken, & Howard, 2012), and is evidenced
on dot probe tasks by shorter reaction times (RT) to probes replacing drug-related images
relative to probes replacing neutral images (Field & Cox, 2008). This RT difference is
considered an index of addiction AB.
Assessing addiction AB may be performed on multiple attentional processes as a function of
the duration that the stimulus is presented. According to basic human perception research,
individuals require an average of 50 milliseconds (ms) to orient attention to a simple visual
stimulus (Duncan, Ward, & Shapiro, 1994), while requiring at least 150 ms to disengage
attention from that stimulus and shift it to another location in space (Theeuwes 2005). On
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tasks involving simultaneous presentation of visually complex drug-related and neutral cues,
AB for a cue presented for ≤ 200 ms is theorized to index automatic, initial orienting toward
drug cues, because orienting, disengagement, and re-orienting to a new complex stimulus is
not possible within 200 ms (Field & Cox, 2008). In contrast, AB for longer duration stimuli
(ranging from 500 to 2000 ms in across studies) is theorized to index higher-order
attentional processes, such as delayed disengagement of attention from drug-related cues
(Field & Cox, 2008) or elaborative cognitive processing (Andreassi, 200; Filion, Dawson, &
Schell, 1993).
AB towards heroin-related stimuli has been observed among methadone-maintained heroin
dependent individuals performing dot probe tasks (Constantinou et al., 2010; Lubman,
Peters, Mogg, Bradley, & Deakin, 2000; Marissen et al., 2006); heroin AB has also been
observed with the flicker change blindness paradigm (Bearre, Sturt, Bruce, & Jones, 2007
and the addiction Stroop task (Marissen et al. 2006). In addition, a particularly sophisticated
study employing ecological momentary assessment via handheld computers revealed that
heroin AB as measured by the addiction Stroop task was elevated one hour prior to episodes
of temptation to use heroin (Waters, Marhe, & Franken, 2011). Although these studies have
established the presence of AB towards illicit opiates among opiate dependent individuals,
to our knowledge no study has identified an AB towards prescription opioids among opioid-
dependent chronic pain patients. In light of the dearth of findings in this potentially
important area, the purposes of the present study were a) to establish the existence of a
prescription opioid AB and b) to determine whether persons suffering from chronic pain
who meet DSM-IV diagnostic criteria for opioid dependence exhibit a significantly greater
AB towards prescription opioid-related stimuli than opioid users who do not meet DSM-IV
criteria for opioid dependence. If so, the presence of a differential AB toward prescription
opioids might be reflective of an addictive process in excess of the physical dependence
symptoms of withdrawal and tolerance occasioned by authorized use of prescription opioids.
Therefore, in the present study a sample of opioid-dependent and nondependent chronic pain
patients taking prescription opioid analgesics completed a dot probe task in which opioid
and neutral images were presented for 200 and 2000 ms to assess for the presence of AB
during attentional orienting and/or disengagement (c.f., Field & Cox, 2008). We
hypothesized that, compared to non-dependent opioid users, opioid-dependent patients
would have a greater AB to opioid-related cues at both stimulus durations. We also assessed
opioid craving to identify relations between opioid AB and appetitive responding. Given the
possibility that opioid cues could also compel attention as a result of reinforcement
conditioning via the analgesic effects of opioids, we examined associations between opioid
AB, pain severity, and pain relief.
METHODS
Participants
Chronic opioid use is defined in clinical guidelines as use of opioids daily or nearly every
day for at least 90 days (Chou et al., 2009; Korff et al., 2008). As such, chronic pain patients
who were currently taking prescription opioid analgesics (hereafter referred to as opioids)
regularly for >3 months were recruited from primary care clinics, pain clinics, and
neurology clinics in Tallahassee, FL through flyers, as well as from online classified ads.
Advertisements were focused on recruiting participants who suffer from and are prescribed
medicine for chronic pain for a study focused on improving ways to address problems with
chronic pain and prescription pain medication. Criteria for opioid dependence and abuse
were assessed with section J of the Mini-International Neuropsychiatric Interview (MINI;
Sheehan et al., 1998). Diagnostic interviews were conducted by clinical assessors trained in
making substance use disorder diagnoses with the MINI. Based on diagnosis, participants
were grouped into one of two groups: a group of chronic pain patients who met DSM-IV
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criteria for prescription opioid dependence (the opioid-dependent group), and a group of
chronic pain patients who used prescription opioids but did not meet DSM-IV criteria for
prescription opioid dependence (the non-dependent opioid user group) or abuse.
The opioid-dependent group consisted of 32 individuals who had taken prescription opioid
medications to treat chronic pain conditions including low back pain (31.3%), cervical pain
(6.3%), fibromyalgia (25.0%), osteoarthritis (3.1%), chronic daily headache (3.1%),
peripheral neuropathy (3.1%), chest pain (6.3%), and systemic scleroderma (3.1%). The
nondependent opioid user group consisted of 33 individuals who had taken prescription
opioid medications to treat chronic pain conditions including low back pain (39.4%),
cervical pain (15.2%), fibromyalgia (21.2%), osteoarthritis (9.1%), extremity pain (3.1%),
peripheral neuropathy (6.1%), and reflex sympathetic dystrophy (3.1%).
The prevalence of opioid analgesic medications (including the opiate morphine, the opioid
agonist tramadol, and the mixed agonist-antagonist buprenorphine) used by opioid-
dependent and non-dependent participants is reported in Table 1. Across the entire sample,
the most frequently reported opioid was hydrocodone, followed by tramadol, oxycodone,
methadone, fentanyl, morphine, and suboxone. Participants also reported using a number of
nonopioid medications to manage pain: nonsteroidal anti-inflammatory drugs (NSAIDS) (n
= 7), cyclobenzaprine (n = 4), metaxalone (n = 1), and methocarbamol (n = 1).
Participants were also assessed for co-morbid alcohol and substance use disorders using
Sections I and J of the MINI but were not excluded from the study if they met diagnostic
criteria for these conditions. Screening did exclude individuals with a history of current
psychotic disorder or who had active suicidal ideation and intent as established by the MINI
(Sheehan et al., 1998). All participants provided written, informed consent and were
compensated $25 for their participation in the study. The study was approved by the human
subjects committee of Florida State University and accords with ethical provisions set in the
Declaration of Helsinki.
Procedures
Participants were instructed to take their prescribed opioid medication as usual on the day of
participation in the study. In a single session, participants completed several validated
questionnaires (as described in the “Measures” section below), followed by the dot probe
task. Participants also made arousal ratings for each image used in the dot probe task in a
separate picture rating task.
Measures
Dot probe task—A dot probe task was used to measure opioid AB. This task was
generated in E-Prime 2.0 (PST Inc., Pittsburgh, PA) and presented on an IBM T60 laptop
with a 15” screen. Each trial began with a fixation cross presented for 500 ms. Next, two
images matched for visual complexity, composition, and figure-ground relationships
appeared side by side on the computer screen. On critical trials, pairs of photos containing
one opioid-related image and one neutral image were presented. On filler trials, pairs of
neutral photos were presented. A set of 12 opioid images were chosen to represent a wide
range of commonly prescribed opioids in a number of forms, including photos of pills (e.g.,
Oxycontin, Vicodin), pill bottles, crushed and powdered opioids for insufflation, and a
syringe next to a vial of injectable morphine. Neutral images included 12 photos culled from
the International Affective Picture System (Lang, Bradley, & Cuthbert, 1997) depicting
household items such as a rolling pin, rubber bands, a lamp, etc. Each pair of images was
presented for either 200 or 2000 ms. Presentation duration and left/right position of the
images was randomized and counterbalanced across 12 filler trials and 64 critical trials.
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Both pictures disappeared, and a target probe (one dot) replaced one of the images after a 50
ms inter-stimulus interval (ISI). Probes appeared for 100 ms, and probe location was
counterbalanced. Participants were instructed to indicate the location of the target by
responding with a left or right button press on a keypad.
Opioid craving—Opioid craving was measured with a prescription opioid version of the
Obsessive Compulsive Drug Use Scale (OCDUS; α = .81 in the present sample) modified
by the authors for this study and scored on a 5-point Likert-type scale that assessed how
often over the past week the respondent experienced craving for opioids (Franken,
Hendriksa, & van den Brink, 2002). OCDUS exhibits convergent validity via significant
correlations with AB and psychophysiological responses to opiate cues (Franken, Kroon,
Wiers, & Jansen, 2000; Zijlstra, Veltman, Booij, van den Brink, & Franken, 2009). The
wording of items was changed slightly to reflect prescription opioid use; e.g., the item “How
strong is the drive to take drugs?” was changed to “How strong is the drive to take your pain
medicine?”
Opioid arousal—Participants were asked to rate how they felt in response to viewing the
opioid cues by rating the perceived arousing quality of opioid photos on a 9 point Likert-
type scale. The arousal scale was anchored with 1 = completely unaroused (e.g., calm,
sluggish, dull) and 9 = completely aroused (e.g., stimulated, excited, jittery). Such rating
scales for stimulus-related arousal have been employed in numerous studies using the
International Affective Picture System (Lang et al., 1997).
Pain severity and relief from pain treatments—Pain severity and relief obtained
from pain treatments (e.g., medication) was assessed with the Brief Pain Inventory-Short
Form, a widely-used, well-validated scale (BPI-SF, α = .88 in the present sample). The BPI-
SF pain severity scale is computed by summing responses on four 11-point scales rating
level of pain (0 = no pain, 10 = pain as bad as you can imagine) at its worst, best, average,
and right now. The BPI-SF assesses pain relief with a single question “In the past 24 hours,
how much relief have pain treatments or medications provided?” scored on an 11-point scale
ranging from 0 to 100% relief.
Data Analysis
With regard to the analysis of AB data for each participant, trials with extreme RTs, defined
as those with RTs 3 SD above or below the individual mean RT (c.f., Field, Mogg, Zetteler,
& Bradley, 2004; Ratcliff, 1993), were eliminated as outliers (for opioid-dependent
individuals, a mean 0.63 ± 1.31 trials were discarded; for non-dependent opioid users, a
mean 0.48 ± 1.31 trials were discarded). Trials on which the probe location was incorrectly
identified were also omitted in AB analyses; opioid-dependents incorrectly identified the
probe location of 14.3% of trials, whereas non-dependent opioid users incorrectly identified
the probe location on 13.6% of trials.
AB scores were calculated by subtracting their mean RT to target probes replacing opioid
photos from their mean RT to target probes replacing neutral photos, such that positive bias
scores indicate an AB toward opioid cues. One-sample Kolmogorov-Smirnov tests revealed
that the distributions of the 200ms AB scores (M = 17.99, SD = 34.31; skewness = .58, SE
= .30; kurtosis = 2.11, SE = .59) and 2000 ms AB scores (M = 5.26, SD = 38.78; skewness =
1.92, SE = .30; kurtosis = 6.72, SE = .59) did not significantly differ from a normal
distribution, p = .698 and p = .164, respectively. We employed analyses of variance
(ANOVA) to identify between-groups (opioid-dependent vs. non-dependent opioid user)
and within-groups (presentation duration) differences in AB scores for stimuli presented for
200 and 2000 ms. ANOVA was also used to identify differences in ratings of arousal for
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opioid-related and neutral photographs on the picture rating task. Pearson correlation
coefficients were used to examine associations between AB scores, opioid craving, opioid
misuse behaviors, pain severity, relief from pain treatments, and mean arousal ratings for
opioid and neutral cues.
Sensitivity analysis
To assure the robustness of our findings, we conducted the following sensitivity analyses.
Though the distribution of the RT data did not significantly differ from normal, we first log
transformed the RTs on trials where the location of the probe was cued by drug cues and the
RTs on trials where the location of the probe was cued by neutral cues to compute log
transformed AB scores. To check for distortions due to skew or kurtosis, we then re-ran the
ANOVA on the log transformed AB data. Next, to ensure that potential between-groups
differences in comorbid alcohol and substance use disorders did not confound AB results,
these variables were controlled for in an additional ANOVA model as covariates. Last,
because tramadol and suboxone putatively have lower abuse liability than other opioid




Summary data for the opioid-dependent individuals (n = 32) and non-dependent opioid users
(n = 33) are shown in Table 2. Opioid-dependent individuals had significantly higher levels
of craving than non-dependent opioid users. The opioid-dependent and non-dependent
opioid user groups did not significantly differ with regard to pain severity or percent relief
from pain treatments, nor did they significantly differ with regard to age or gender
composition. Pearson chi-square analysis indicated that the opioid-dependent and non-
dependent opioid user groups did not significantly differ with regard to the types of opioids
used, nor did they significantly differ with regard to history of comorbid alcohol and
substance use disorders. Among the opioid-dependent group, 5 individuals met diagnostic
criteria for alcohol use disorders and 4 met criteria for substance use disorders, whereas
among the non-dependent opioid user group, 2 individuals met criteria for alcohol use
disorders and 2 met criteria for substance use disorders. Cannabis was the most commonly
reported illicit drug used by participants (n = 12), followed by cocaine (n = 2) and heroin (n
= 1).
Between-groups differences in opioid attentional bias
A 2 (Group: opioid-dependents, non-dependent opioid users) × 2 (Presentation duration:
200ms, 2000ms) repeated-measures ANOVA, with photo presentation duration (200 or 2000
ms) as a within-subjects factor and group (opioid-dependent vs. non-dependent opioid user)
as a between-subjects factor revealed a significant effect for presentation duration, F(1,62) =
5.97, p = .017, ηρ2 = .09, as well as a significant group × presentation duration interaction,
F(1,62) = 8.51, p = .005, ηρ2 = .12. Post-hoc tests indicated that opioid-dependent
individuals had significantly greater 200ms AB than opioid non-dependents, F(1,64) = 4.98,
p = .029, ηρ2 = .07; at this brief stimulus duration, opioid misusers had shorter reaction
times to probes replacing opioid cues relative to probes replacing neutral cues, indicating the
presence of an AB toward opioid cues (see Figure 1). However, there was no significant
between-groups difference in 2000ms AB, F(1,63) = 1.34, p = .25, ηρ2 = .02. Within-group,
one sample t-tests were used to determine whether these AB scores were significantly
different than zero. Among opioiddependent individuals, the mean 200ms AB was
significantly different from zero, t(31) = 5.27, p < .001, whereas the mean 2000ms AB was
not, t (30) = −.08, p = .93. Among non-dependent opioid users, neither the mean 200ms nor
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the mean 2000ms AB were significantly different from zero, t(32) = 1.32, p = .20, and t(32)
= 1.34, p = .19, respectively. The pattern and significance of ANOVA results did not differ
substantially when repeated on log reaction time data. Similarly, the pattern and significance
of results did not differ when persons taking tramadol or suboxone were omitted from the
analyses, or when comorbid alcohol/substance dependence and abuse diagnoses were
controlled for in the ANOVA model as covariates.
Arousal ratings
Mean arousal ratings were calculated for opioid-related and neutral images for each
participant. A 2 × 2 ANOVA was conducted on the arousal ratings, with cue type (opioid vs.
neutral) and participant group (opioid-dependent vs. non-dependent opioid user) as
independent variables. The arousal analysis revealed a significant main effect for cue type,
F(1,63) = 20.76, p < .001, ηρ2 = .25, but no significant group × cue type interaction effect,
F(1,63) = 1.42, p = .24, ηρ2 = .02. Both opioid-dependent individuals and non-dependent
opioid users rated the opioid photos as more arousing than the neutral photos.
Associations between Opioid AB and Opioid-Related Clinical Factors
Correlations between opioid AB and opioid-related clinical variables were computed within
the opioid-dependent and non-dependent opioid user groups separately. Among opioid-
dependent individuals, opioid craving as measured by the OCDUS was significantly
correlated with opioid 200 ms AB, r = .36, p = .046. In contrast, 200 ms AB was not
significantly associated with pain severity or relief from pain treatments among these
opioid-dependent individuals. Among this opioid-dependent subsample, 2000 ms AB was
not significantly correlated with opioid craving, percent of pain relief provided by
treatments, or pain severity.
With regard to the subsample of non-dependent opioid users, 200 ms AB was significantly
correlated with relief from pain treatments, r = .37, p = .03, but was not significantly
associated with opioid craving or pain severity. Among non-dependent opioid users 2000 ms
AB was not significantly associated with craving, relief from pain treatments, or pain
severity.
Both within and across the opioid-dependent and non-dependent opioid user groups, the
subjective arousal of the opioid photos was not significantly associated opioid AB, nor were
the arousal ratings associated with most of the other clinically-relevant variables assessed in
this study. However, among opioid-dependent individuals, accuracy on the dot probe task
was inversely correlated with arousal ratings of opioid photos, r = −.37, p = .04. In addition,
across the entire sample, opioid craving was significantly associated with arousal ratings of
opioid photos, r = .34, p = .006.
DISCUSSION
The current study provides the first evidence that opioid-dependent chronic pain patients
exhibit an AB towards prescription opioid-related cues beyond that of a comparison group
of non-dependent opioid users with chronic pain. This AB was evident for opioid cues
presented for brief (200 ms), but not for long (2000 ms) durations. In addition, opioid-
dependent individuals reported significantly higher levels of craving than non-dependent
opioid users, but did not significantly differ with regard to pain severity or degree of relief
from pain treatments. Among opioid-dependent individuals, the 200 ms AB was
significantly positively associated with opioid craving, whereas among non-dependent
opioid users, the 200 ms AB was significantly positively associated with degree of relief
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from pain treatments. This differential pattern of association may suggest that the 200 ms
AB reflects appetitive responses among opioid-dependent individuals.
The AB towards opioid-related cues observed among this sample of opioid-dependent
chronic pain patients occurred for stimuli presented for 200 ms. Some investigators contend
that the 200 ms AB indexes automatic attentional orienting to motivationally salient stimuli
that arises out of a history of conditioning (Field & Cox, 2008). Indeed, exposure to cues
associated with recurrent episodes of substance use results in a conditioned appetitive
response (O’Brien et al. 1998). Neural sensitization to the rewarding effects of the substance
and to substance-related cues is theorized to impart motivational or incentive salience to
these cues coupled with a “wanting” for the substance (Robinson & Berridge, 2001;
Robinson & Berridge, 2008). It is possible that the opioid images held greater incentive
salience for opioid-dependent chronic pain patients than the neutral images, and thus biased
attention towards the location of the probe at an early stage of attentional selection. This
interpretation is consistent with our finding that the degree to which an individual’s attention
was biased towards these brief exposures to drug cues was positively associated with their
self-reported craving for opioids. Although in clinical practice chronic pain patients often
deny experiencing a euphoric effect from taking opioids and tend to be more concerned with
avoiding the experience of pain between opioid doses than with craving, research suggests
that a substantial proportion of chronic pain patients do report craving for prescription
opioids (Wasan et al., 2009; Wasan et al., 2012). In the current study, participants who
experienced higher levels of craving as indicated by the presence of compulsive and
intrusive thoughts and feelings related to opioid use had larger AB towards opioid cues than
those who reported less craving. In contrast, opioid-dependent individuals did not evidence a
significant AB toward opioid cues presented for 2000 ms. These findings may suggest that
among the current opioid-dependent subsample, attention was biased at earlier stages of
appetitive orienting, rather than at the later stages of attentional disengagement or
elaboration. To test this hypothesis, eye tracking and event-related potential (ERP) analyses
are needed to triangulate data from the dot probe task.
Individual differences analyses suggested that the 200 ms AB among non-dependent users
was significantly associated with the degree of relief obtained from pain treatments. Thus,
among this non-dependent, opioid-using subsample, it is possible that attention to brief
opioid cues was influenced by reinforcement conditioning stemming from the analgesic
effect of opioids (Baker, Piper, McCarthy, Majeskie, & Fiore, 2004; Fields, 2004). Indeed,
pain relief and reward appear to share common neural substrates (Baliki, Geha, Fields,
Apkarian, 2010). However, it should be noted that as a group the non-dependent opioid
users did not exhibit a significant mean 200 ms AB, and the observed relation between AB
and pain relief among this subsample was only evident in correlational analyses.
Alternatively, the observed results may be explicated by a learning theory explanation
(Pearce & Bouton, 2001). From this perspective, over the course of repeated opioid use, the
sight of a pill or pill bottle may become a conditioned stimulus (the CS) that is paired with
pharmacologic action of opioids in the brain (the UCS). In the typical experience of an
opioid-using chronic pain patient, this pairing may remain consistent and intact – the sight of
opioid medication is followed by consumption of the opioid and the resultant psychoactive
effect. However, in the dot probe task used in the current study, these conditioned stimuli
are presented in the absence of the drug - a procedure that is methodologically similar to a
Pavlovian extinction trial (Pavlov, 1927). Extinction trials elicit enhanced attention to the
CS, putatively due to a prediction error generated by the presentation of the CS without the
UCS (Larrauri & Schmajuk, 2008; Pearce & Hall, 1980). As such, the dot probe task itself
may evoke heightened attention to opioid cues for persons with a history of opioid use.
Because the task was held constant between groups, observed differences in opioid AB may
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stem from the comparatively greater associative strength of opioid cues for opioid-
dependent patients, resulting in a more robust prediction error when the CS is not followed
by the UCS on dot probe trials (Pearce & Bouton, 2001).
Notably, both the opioid-dependent and the non-dependent opioid users found the opioid-
related images presented in the dot probe task to be more arousing than neutral images, and
across the entire sample, opioid arousal ratings were significantly positively correlated with
opioid craving. Stimulus-related arousal reflects bottom-up processing via a cortico-limbic
loop (Kilpatrick & Cahill, 2003) and drug preoccupation and craving are posited to be
subserved via a similar cortico-limbic loop (Koob & Volkow, 2009) - activation of this
neural circuitry is known to prime attention (Ledoux, 1995). Thus, one possible
neurobiological explanation of these findings is that presentation of opioid cues may have
activated cortico-limbic circuits, particularly among opioid-dependent individuals and
thereby primed attention for the appearance of the probe in its stead. A primary model of
drug addiction more broadly posits that drug dependence is associated with modulation and
long-term changes in the neurobiological function of the mesolimbic dopamine reward
system (Wolf, 2002; see Koob & Volkow, 2009). Human neuroimaging research has
provided preliminary support for this model by finding that self-reported craving predicts
the magnitude of dopamine release in the striatum elicited by drug cues (Volkow et al.
2008). Furthermore, aberrant neural function in frontal-executive regions subserving
attention and inhibitory control is reported across multiple substance abuse populations
including heroin (Yang et al. 2009), cocaine (Garavan, Kaufman, & Hester, 2008), and
nicotine (Froeliger, Modlin, Kozink & McClernon, 2011; Froeliger, Modlin, Kozink, Wang
& McClernon, 2011) dependent individuals. Among alcohol-dependent persons, degree of
AB toward alcohol cues has been significantly associated with increased activation in the
ventral striatum, insula, inferior frontal gyrus, and anterior cingulate, insula, and ventral
striatum (Vollstädt-Klein, et al., 2011). Speculatively, dysregulation in similar frontal and
subcortical regions might partially explain the observed associations between AB and
craving response among this sample of individuals exhibiting clinically-disordered,
addictive behavior towards prescription opioid medications.
Strengths of the study include the novel application of a dot probe task, a validated
behavioral measure that has been broadly employed in cognitive neuroscience research, to
help illuminate a clinical issue of considerable significance to public health in the U.S. Yet,
the present study was limited in several respects. No biochemical measures were used to
corroborate self-reports of opioid use; urine toxicology screens would have helped to
establish the presence of inclusion and exclusion criteria. Unfortunately, no resources were
available for urine toxicology screens. We did not conduct formal sobriety testing at the time
of the study assessment, nor did we measure opioid withdrawal. It is possible that AB effects
were influenced by acute opioid intoxication or withdrawal, as many pain patients withdraw
even on stable doses and/or between doses of short-acting medications. Relatedly, chronic
pain patients tend to experience impaired concentration, and sitting for long periods of time
during the testing procedure may have been painful for these patients; thus performance on
the dot probe task could have been influenced by these factors. Also, we employed a
prescription opioid version of the OCDUS, a measure which was originally designed to
assess craving for illicit drugs like heroin, not prescribed opioid analgesics. Although this
modified version of the scale evidenced good internal consistency, the measure has not been
formally validated in this context. However, given the significant correlation between this
modified OCDUS and a behavioral measure of appetitive processes (i.e., 200 ms AB) and
arousal elicited by opioid photos, this scale does seem to be capturing the construct of
interest in this sample of opioid-dependent chronic pain patients. Lastly, though all
participants had been treated for chronic pain with opioids for more than 90 days, we did not
have information on the exact duration of opioid use or chronic pain. While we asked an
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open-ended question about opioid dosing, missing data and the extreme variability in quality
of responses made it impossible to quantify this variable for use as a covariate in the current
study. It is possible that some of the observed differences in AB stem from variables
unaccounted for in the present analysis, such as education level, mood, activity interference,
use of non-opioid medications, and past history of pain-related surgery. For example,
patients who have taken opioids for a longer period of time are likely to exhibit more severe
opioid misuse than those who have taken opioids for less time (Green, Black, Serrano,
Budman, & Butler, 2011), and thus chronicity of pain condition and duration of opioid
dosing may have contributed to opioid AB. Therefore, study findings should be considered
preliminary in nature and will require rigorous validation.
Future studies should redress the foregoing limitations and couple AB measurement with
psychophysiological and neuroimaging paradigms to more precisely elucidate mechanisms
underlying this phenomenon (e.g., Garland, 2011). In particular, eye tracking and event-
related potential (ERP) analyses could be used to isolate the temporal components and
dynamics of the opioid AB, and functional magnetic resonance imaging (fMRI) studies
might identify the neural substrates of dysregulated bottom-up and top-down neural circuitry
function. Furthermore, it would be optimal to include a third comparison group of opioid
users without chronic pain to disentangle relationships between opioid AB and chronic pain.
In addition, measures of opioid misuse (e.g., the Current Opioid Misuse Measure, Butler et
al., 2007) could be used as an alternative to or in conjunction with DSM-IV criteria to
determine if patients who are at higher risk for disordered opioid use exhibit greater opioid
AB. Lastly, to disentangle the effects of opioid dose-response curves from addictive
responses, relative opioid potency estimates and opioid dosing frequency and duration
histories should be controlled for in future analyses.
In sum, this study presents the first evidence of an AB towards prescription opioid
analgesics among opioid-dependent chronic pain patients. Although many such patients are
reluctant to report addictive tendencies towards opioid medication, these individuals may
exhibit behaviors reflective of a tendency to preferentially attend to opioid-related stimuli
which could indicate the presence of an implicit appetitive process that may operate beneath
consciousness. Thus, should opioid AB continue to be observed among opioid-dependent
chronic pain patients in future studies, this measure may hold utility as a clinical assessment
tool. Hypothetically, when coupled with ever-worsening hyperalgesia and hypervigilance for
pain (Garland, in press), attentional fixation on opioid cues may fuel a downward spiral of
compulsive drug use that leads to opioid addiction and significant functional impairment.
Novel interventions that can facilitate attentional regulation of cue-reactivity (e.g.,
mindfulness-based therapies; see Garland, 2011; Garland, Gaylord, Boettiger, & Howard,
2010) while reducing chronic pain may be especially efficacious means of addressing this
pernicious and prevalent social problem.
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Attentional bias 200 and 2000 ms stimulus presentation durations among opioid dependent
(n = 32) and non-dependent opioid-using chronic pain patients (n = 33). Positive values
denote a bias toward opioid photos. Negative values denote a bias away from opioid photos.
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Table 1





Hydrocodone 23 (71.9%) 20 (60.6%)
Tramadol 5 (15.6%) 7 (21.2%)
Oxycodone 4 (12.5%) 4 (12.1%)
Fentanyl 1 (3.1%) 4 (12.1%)
Morphine 2 (6.3%) 2 (6.1%)
Methadone 1 (3.1%) 3 (9.1%)
Buprenorphine 1 (3.1%) 0 (0.0%)
*
No statistically significant difference in prevalence of opioid medication used per group.
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Table 2








Age (years) 44.86 (SD = 15.45,
range 18 – 65)
48.59 (SD = 11.07,
range 20 – 68)
1.07 .27
Gender (men, %) n = 11 (34.4%) n = 16 (48.0%) 1.60 .31
Opioid Craving 16.42 (SD = 8.70,
range 1 – 29)
9.18 (SD = 5.53,









n = 4 (12.4%) n = 2 (6.1%) .80 .43
Pain Severity 5.26 (SD = 1.78,
range 1 – 7.50)
5.88 (SD = 1.56,




53.89 (SD = 23.82,
range 20 – 90)
57.67 (SD = 23.79,
range 10 – 80)
.70 .48
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